Effective Combination Therapy of Deferiprone and deferoxamine for the Rapid Clearance of Excess Cardiac IRON and the Prevention of Heart Disease in Thalassemia. The Protocol of the International Committee on Oral Chelators

REFERENCES

• Kontoghiorghes GJ, Neocleous K, Kolnagou A. Benefits and risks of deferiprone in iron overload in thalassemia and other conditions. Drug Saf 2003; 26(8)553–584, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Modell B, Berdoukas V. The clinical approach to thalassemia. Grune & Stratton, London 1984
   Google Scholar
• Kontoghiorghes GJ, Pattichis K, Neocleous K, Kolnagou A. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Curr Med Chem 2004; 11(16)2161–2183, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Advances in oral iron chelation in man. Int J Haematol 1992; 55(1)27–38, [CSA]
   PubMed Web of Science ®Google Scholar
• Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and deferoxamine. Br J Haematol 1998; 103(2)361–364, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Aydinok Y, Nisli G, Kavakli K, Coker C, Kantar M, Cetingul N. Sequential use of L1 and desferrioxamine in primary school children with thalassemia major in Turkey. Acta Haematol 1999; 102(1)17–21, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Giardina PJ, Grady RW. Chelation therapy in β-thalassemia: an optimistic update. Semin Haematol 2001; 38(4)360–366, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis Ch. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. Haematologica 2003; 88(12)1423–1425, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Meleventi C, Di Gregorio F, Buratini MG, Terzoli S, Gabutti V. Survival and causes of death in thalassemia major. Lancet 1989; ii(8653)27–29, [CROSSREF], [CSA]
   Web of Science ®Google Scholar
• Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK register. Lancet 2000; 355(9220)2051–2052, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Eracleous E, Economides Ch, Kolnagou A. Advances in iron overload therapies. Prospects of effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56–252, L1NAll, and their combinations. Curr Med Chem 2005; 12(23)2663–2681, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Marcus RE, Davies SG, Bantock HM, Underwood SR, Walton S, Huehns ER. Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassaemia major. Lancet 1984; i(8373)392–393, [CROSSREF], [CSA]
   Google Scholar
• Cohen A, Martin M, Schwartz E. Depletion of excessive liver iron stores with desferrioxamine. Br J Haematol 1984; 58(2)369–373, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Cappelini MD. Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Prac Res Clin Haematol 2005; 18(2)289–298, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Fessas Ch, Papatryphonas A, Economides Ch, Kontoghiorghes GJ. Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia. Br J Haematol 2004; 127(3)360–361, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennel DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet 2002; 360(9332)516–520, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Peng C-T, Chow K-C, Chen J-H, Chiang Y-P, Lin T-Y, Tsai C-H. Safety monitoring of cardiac and hepatic systems in β-thalassaemia patients with chelating treatment in Taiwan. Eur J Haematol 2003; 70(6)392–397, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Kolnagou A. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet 2003; 361(9352)184, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, Porter JB, Walker JM, Pennell DJ. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004; 127(3)348–355, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Mavrogeni SI, Gotsis ED, Markussis V, Tsekos N, Politis C, Vretou E, Kremastinos D. T2 relaxation time study of iron overload in β-thalassemia. MAGMA 1998; 6(1)7–12, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennel DJ. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22(23)2171–2179, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Angellucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, Galimberti M, Polchi P, Lucarelli G. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000; 343(5)327–331, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Nielsen P, Fischer R, Engelhardt R, Tondury P, Gabbe EE, Janka GE. Liver iron stores in patients with secondary haemochromatosis under iron chelation therapy with deferoxamine or deferiprone. Br J Haematol 1995; 91(4)827–833, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Effects of ICL670 (deferasirox) on cardiac iron concentrations. Lancet 2005; 366(9488)804, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Nick H, Acklin P, Lattmann R, Buechlmayer P, Hauffe S, Hauffe S, Schupp J, Alberti D. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem 2003; 10(12)1065–1076, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, Krebs-Brown AJ, Anderson JR, Alberti D, Sizer KC, Nathan DG. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003; 361(9369)1597–1602, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia. J Clin Pharmacol 2003; 43(6)565–572, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Donovan JM, Plone MA, Wonke B. The safety and pharmacokinetics of GT56–252, a novel orally available iron chelator. Eur J Clin Invest 2004; 34(Suppl 1)39, [CSA]
   Google Scholar
• Sheppard L, Kontoghiorghes GJ. Competition between L1, desferrioxamine and other chelators for iron and the effect of other metal ions on iron binding. Arzn Forsch/Drug Res 1993; 43(6)659–663, [CSA]
   PubMed Web of Science ®Google Scholar
• Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 2004; 103(3)1934–1936, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar